🇺🇸@COVID19Up: The U.S. government has agreed to purchase $1.2 billion worth of an experimental COVID-19 treatment from Merck if the drug is approved by regulators.

Molnupiravir, which is currently in Phase 3 clinical trials, is being tested on study participants who have been diagnosed with COVID-19, aren’t hospitalized and have one or more risk factors, such as diabetes, obesity or old age, associated with worse outcomes from the disease.

Merck plans to apply to the FDA for emergency use authorization in the second half of 2021.

Could this be why Merck attacked the safety of its own decades old, extremely safe drug called Ivermectin?

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *